DSE

DSE

Target · Glycosaminoglycan enzyme

DSE Dermatan sulfate epimerase · squamous cell carcinoma antigen recognized by T cells 2

DSE (dermatan sulfate epimerase, also known as DSEPI, DS-Epi1 and SART2) is an enzyme that converts D-glucuronic acid to L-iduronic acid during the biosynthesis of the glycosaminoglycan dermatan sulfate. It was first described as a tumour-rejection antigen. Browse Assay Genie's current range of DSE research reagents below, or read on for the biology behind the target.

Membrane-bound enzymeDermatan sulfate biosynthesisTumour-rejection antigen
958 aa
Protein length
~110 kDa
Molecular weight
6q22.1
Gene locus
EC 5.1.3.19
Enzyme class
Target information

What is DSE (dermatan sulfate epimerase)?

DSE catalyses the conversion of D-glucuronic acid to L-iduronic acid (IdoUA) residues. This epimerisation step plays an important role in the biosynthesis of dermatan sulfate, a glycosaminoglycan (mucopolysaccharide). The enzyme is classed as EC 5.1.3.19 and belongs to the dermatan-sulfate isomerase family.

UniProt lists DSE as a membrane-associated protein found in the endoplasmic reticulum, Golgi apparatus, cytoplasmic vesicle and microsome membranes. NCBI Gene describes the encoded protein as localised to the endoplasmic reticulum. The human DSE gene has a mouse ortholog, Dse. Alternative splicing produces multiple transcript variants. A related pseudogene lies on chromosome 9, and a paralogous gene exists on chromosome 18.

The alias SART2 and the previous name squamous cell carcinoma antigen recognized by T cells 2 reflect the original identification of the protein as a tumour-rejection antigen. It carries tumour epitopes able to induce HLA-A24-restricted, tumour-specific cytotoxic T lymphocytes in cancer patients, and has been proposed as useful for specific immunotherapy. Mutations in the DSE gene cause musculocontractural Ehlers-Danlos syndrome, linking the enzyme to connective tissue biology.

Glycosaminoglycan biosynthesis

DSE converts D-glucuronic acid to L-iduronic acid, making it a key enzyme for studying how dermatan sulfate chains are built.

Tumour immunology

As a tumour-rejection antigen, DSE carries epitopes that induce HLA-A24-restricted cytotoxic T lymphocytes in cancer patients.

Immunotherapy research

NCBI Gene notes that DSE tumour epitopes may be useful for specific immunotherapy, making it a target of interest in antigen-directed approaches.

Connective tissue disorders

Mutations in DSE cause musculocontractural Ehlers-Danlos syndrome, so the enzyme is relevant to research on inherited connective tissue disease.

Background

DSE frequently asked questions

What does DSE do?

DSE converts D-glucuronic acid to L-iduronic acid residues. This epimerisation plays an important role in the biosynthesis of dermatan sulfate, a glycosaminoglycan. The enzyme is membrane-associated, with reported locations in the endoplasmic reticulum and Golgi apparatus.

Why is DSE also called SART2?

SART2 stands for squamous cell carcinoma antigen recognized by T cells 2, a previous name for the gene. It reflects the protein's identification as a tumour-rejection antigen. Other aliases for DSE include DSEPI and DS-Epi1, and the official name is dermatan sulfate epimerase.

Is DSE linked to disease, and is it conserved in mouse?

Mutations in the DSE gene cause musculocontractural Ehlers-Danlos syndrome. The protein is also a tumour-rejection antigen studied for immunotherapy. A mouse ortholog, Dse, exists; check the datasheet of any product for its validated reactivity.

Explore

Related targets

Other glycosaminoglycan biosynthesis enzymes, dermatan sulfate pathway proteins and tumour antigen targets with products at Assay Genie.

Gene and protein annotations from HGNC, NCBI Gene and UniProt Q9UL01; product specifications from Assay Genie datasheets.

DSE Product listing